# Wuhan YZY Biopharma

Source: https://onco.cc/companies/wuhan-yzy-biopharma/  
OnCo record `wuhan-yzy-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

YZY Biopharma is a Wuhan company listed in Hong Kong that builds bispecific antibodies, including one given directly into the abdomen to control fluid build-up from cancer.

## Summary

Wuhan YZY Biopharma, founded in 2010 and listed in Hong Kong, develops bispecific antibodies on its YBODY platform. Its lead product M701, an EpCAM and CD3 bispecific given intraperitoneally for malignant ascites, and M802, a HER2 and CD3 bispecific, are in trials in China, with the ascites programme in phase 3 registered on ClinicalTrials.gov under YZY as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Wuhan YZY Biopharma Co., Ltd.; YZY Biopharma; 武汉友芝友生物
- Tags: ctgov-sponsor
- HQ: Wuhan
- Type: biotech
- Website: http://www.yzybio.com

## Sources

- Official website: http://www.yzybio.com
- ClinicalTrials.gov: trials led by Wuhan YZY Biopharma Co., Ltd.: https://clinicaltrials.gov/search?lead=Wuhan%20YZY%20Biopharma%20Co.%2C%20Ltd.
- Wikidata: https://www.wikidata.org/wiki/Q30260850

## Connected records

- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/wuhan-yzy-biopharma.json